Exposure to PFAS chemicals is linked to fat buildup in the liver and disrupted bile flow, which are key features of non-alcoholic fatty liver disease, through interference with specific metabolic genes and signaling pathways.
Claim Context
PFAS exposure is associated with hepatic lipid accumulation and disruption of bile acid metabolism, mediated by suppression of NUDT7 and activation of PPARα, which may contribute to the development of metabolic dysfunction-associated steatotic liver disease (MASLD) in exposed individuals.
“Gou et al. reported that PFOA and PFOS suppress transcription of the Nudix hydrolase 7 (NUDT7) gene. NUDT7 encodes an acetyl-CoA hydrolase that regulates peroxisomal fatty acid β-oxidation. Downregulation of NUDT7 reduces fatty acid oxidation and promotes intracellular accumulation of triglycerides and cholesterol.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of studies measuring liver fat and PFAS levels could determine whether higher PFAS exposure correlates with increased liver fat content in humans.
A systematic review and meta-analysis of 15+ studies using MRI-PDFF or biopsy to quantify liver fat in adults with measured serum PFAS (PFOA, PFOS), adjusting for alcohol, diabetes, and BMI, to estimate pooled effect size of PFAS on hepatic steatosis.
An RCT could determine whether reducing PFAS exposure leads to improvement in liver fat content in individuals with elevated exposure.
A double-blind RCT of 150 adults with elevated serum PFAS (>8 ng/mL) and MRI-confirmed hepatic steatosis (>5% fat), randomized to receive certified PFAS-removing water filters (intervention) or standard filters (control) for 12 months, with primary outcome being change in liver fat percentage by MRI-PDFF.
A prospective cohort could establish whether baseline PFAS levels predict progression to MASLD over time.
A prospective cohort of 3,000 adults aged 35–65 with normal liver function, with baseline serum PFAS measured and annual liver fat assessment by MRI-PDFF over 10 years, adjusting for diet, physical activity, and metabolic syndrome components.
A case-control study could compare PFAS levels in individuals with biopsy-confirmed MASLD versus those with normal liver fat.
A matched case-control study of 400 individuals with biopsy-confirmed MASLD (NAS score ≥5) and 400 controls with normal liver fat on biopsy, matched for age, sex, BMI, and diabetes status, with archived serum PFAS measured from samples collected 2–5 years prior to biopsy.
A cross-sectional study could identify whether individuals with higher PFAS levels at a single time point also have higher liver fat content.
A national cross-sectional survey of 5,000 adults with simultaneous measurement of serum PFAS and liver fat by MRI-PDFF, stratified by region, occupation, and dietary habits.